Clinical trial results:
A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

Summary

EudraCT number	2015-005455-28
Trial protocol	Outside EU/EEA
Global end of trial date	15 April 2020

Results information

Result version number	v1 (current)
This version publication date	29 October 2020
First version publication date	29 October 2020

Trial information

Trial identification

Sponsor protocol code	CN001-006

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02515669
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-001793-PIP01-15
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 April 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	15 April 2020
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study was to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.

Protection of trial subjects:

All study subjects and parents, guardians, or legally acceptable representatives were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 December 2015
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	United States: 39
Worldwide total number of subjects	43
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	43
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Doses for this study are based upon achieving a moderate to high degree of suppression in serum free myostatin at steady-state trough across 3 dose levels. A body weight-tiered, fixed-dose strategy targeting moderate (>50%), high (>85%) and near complete (>95%) suppression of serum free myostatin was used to select the three doses for the study.

Pre-assignment

Screening details:

Starting at Week 5, participants whose weight exceeded or dropped below the dosing weight tier to which they were assigned (by >1kg) were assigned to the new corresponding body weight-based dose within the participants assigned panel.

Period 1

Period 1 title	24 Week Double-Blind Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo subcutaneous injections on specified days

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo subcutaneous injections on specified days.

Arm title	Panel 1 RO7239361

Arm description:

RO7239361 subcutaneous injections on specified days. The Panel 1 dose targets achievement of > 50% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. The Panel 1 body weight tier dose is >15kg at a dose of 4 mg (milligram) /0.8 mL (millilitre).

Arm type	Experimental
Investigational medicinal product name	RO7239361
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants in Panel 1 received 4 mg RO7239361 on specified days.

Arm title	Panel 2 RO7239361

Arm description:

RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL

Arm type	Experimental
Investigational medicinal product name	RO7239361
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361 on specified days.

Arm title	Panel 3 and Expansion Panel RO7239361

Arm description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Arm type	Experimental
Investigational medicinal product name	RO7239361
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361 on specified days.

Number of subjects in period 1	Placebo	Panel 1 RO7239361	Panel 2 RO7239361
Started	11	7	6
Completed	11	7	6

Number of subjects in period 1	Panel 3 and Expansion Panel RO7239361
Started	19
Completed	19

Period 2

Period 2 title	228 Week Open-Label Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes

Arm title	Panel 1 RO7239361

Arm description:

RO7239361 subcutaneous injections on specified days. The Panel 1 dose targets achievement of > 50% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. The Panel 1 body weight tier dose is >15kg at a dose of 4 mg (milligram) /0.8 mL (millilitre).

Arm type	Experimental
Investigational medicinal product name	RO7239361
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants in Panel 1 received 4 mg RO7239361 on specified days.

Arm title	Panel 2 RO7239361

Arm description:

RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL

Arm type	Experimental
Investigational medicinal product name	RO7239361
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361 on specified days.

Arm title	Panel 3 and Expansion Panel RO7239361

Arm description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Arm type	Experimental
Investigational medicinal product name	RO7239361
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361 on specified days.

Number of subjects in period 2	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361
Started	9	8	26
Completed	0	0	0
Not completed	9	8	26

Subject Request to Discontinue Treatment	-	2	3
Unspecified	-	1	4
Missing	2	2	2
Administrative Reason by Sponsor	7	2	17
Lack of efficacy	-	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Placebo subcutaneous injections on specified days	
Reporting group title	Panel 1 RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 1 dose targets achievement of > 50% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. The Panel 1 body weight tier dose is >15kg at a dose of 4 mg (milligram) /0.8 mL (millilitre).	
Reporting group title	Panel 2 RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL	
Reporting group title	Panel 3 and Expansion Panel RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL	

Reporting group values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361
Number of subjects	11	7	6
Age categorical Units: Subjects			
Children (2-11 years)	11	7	6
Age Continuous Units: Years			
arithmetic mean	8.8	8.0	8.0
standard deviation	± 1.33	± 2.24	± 1.79
Sex: Female, Male Units: Participants			
Female	0	0	0
Male	11	7	6

Reporting group values	Panel 3 and Expansion Panel RO7239361	Total	
Number of subjects	19	43	
Age categorical Units: Subjects			
Children (2-11 years)	19	43	
Age Continuous Units: Years			
arithmetic mean	8.1		
standard deviation	± 1.81	-	

Sex: Female, Male Units: Participants			
Female	0	0	
Male	19	43	

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo subcutaneous injections on specified days	
Reporting group title	Panel 1 RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 1 dose targets achievement of > 50% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. The Panel 1 body weight tier dose is >15kg at a dose of 4 mg (milligram) /0.8 mL (millilitre).	
Reporting group title	Panel 2 RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL	
Reporting group title	Panel 3 and Expansion Panel RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL	
Reporting group title	Panel 1 RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 1 dose targets achievement of > 50% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. The Panel 1 body weight tier dose is >15kg at a dose of 4 mg (milligram) /0.8 mL (millilitre).	
Reporting group title	Panel 2 RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL	
Reporting group title	Panel 3 and Expansion Panel RO7239361
Reporting group description:	
RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL	
Subject analysis set title	Panel 2 RO7239361 12.5mg
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL	
Subject analysis set title	Panel 2 RO7239361 20mg
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL. The dose was not administered at Days 1, 15, 22, 29 and 84.	
Subject analysis set title	Panel 3 RO7239361 35mg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. RO7239361 subcutaneous injections on specified days, The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL

Subject analysis set title	Expansion Panel RO7239361 35mg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Subject analysis set title	Expansion Panel RO7239361 50mg
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Subject analysis set title	Panel 3 RO7239361
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Subject analysis set title	Expansion Panel RO7239361
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Subject analysis set title	Panel 3 RO7239361
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Subject analysis set title	Placebo, then RO7239361
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Placebo subcutaneous injections on specified days. At the end of the DB period these participants switched to treatment to treatment with RO7239361 at dose levels of either Panel 1, Panel 2 or Panel 3.

Subject analysis set title	Panel 1 RO7239361 Whole Study
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 1 dose targets achievement of > 50% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. The Panel 1 body weight tier dose is >15kg at a dose of 4 mg (milligram) /0.8 mL (millilitre).

Subject analysis set title	Panel 2 RO7239361 Whole Study
Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 2 dose targets achievement of > 85% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 2 body weight tier doses are =>15kg to =< 45kg at a dose of 12.5 mg /0.25 mL and =>45kg at a dose of 20 mg /0.4 mL

Subject analysis set title	Panel 3 and Expansion Panel RO7239361 Whole Study

Subject analysis set type	Sub-group analysis

Subject analysis set description:

RO7239361 subcutaneous injections on specified days. The Panel 3 and Expansion Panel dose targets achievement of > 95% suppression in levels of free myostatin at trough after 5 weeks of weekly dosing. Panel 3 and Expansion body weight tier doses are =>15kg to =< 45kg at a dose of 35 mg /0.7 mL and =>45kg at a dose of 50 mg /1.0 mL

Primary: Safety Summary for the 24 Week Double-Blind Phase

End point title	Safety Summary for the 24 Week Double-Blind Phase[1]

End point description:

Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Primary

End point timeframe:

Baseline to Week 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were planned for this safety endpoint.

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	7	6	19
Units: percentage of participants				
number (not applicable)				
Death	0	0	0	0
Adverse Events (AEs)	81.8	71.4	100.0	94
AEs leading to study withdrawal	0	0	0	0
Serious Adverse Events (SAE)	9.1	0	0	5.3
Very Severe AEs	0	0	0	0
Severe AEs	0	0	0	0
Related AEs	27.3	14.3	50.0	36.8

Statistical analyses

No statistical analyses for this end point

Primary: Safety Summary up to Week 72

End point title	Safety Summary up to Week 72[2]

End point description:

Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 72. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Primary

End point timeframe:

Baseline to Week 72

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were planned for this safety endpoint.

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	8	26	
Units: percentage of participants				
number (not applicable)				
Death	0	0	0	
Adverse Events (AEs)	100.0	100.0	96.2	
AEs leading to study withdrawal	0	0	0	
Serious Adverse Events (SAE)	0	25.0	7.7	
Very Severe AEs	0	0	0	
Severe AEs	0	25.0	7.7	
Related AEs	77.8	62.5	50.0	

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW doses.

End point title	Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW doses.[3]

End point description:

PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. No participants received the Panel 2 20mg dose.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 hours (h) postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results are only reported for the arms receiving the doses of RO7239361 as indicated.

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	6	19	
Units: ng/ml				
geometric mean (geometric coefficient of variation)	3217 (± 15.8)	8490 (± 21.5)	24242 (± 26.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW dose.

End point title	Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW dose.[4]

End point description:

PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. 9999=not calculable as data are reported for one subject.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results are only reported for the arm receiving the dose of RO7239361 as indicated.

End point values	Panel 3 and Expansion Panel RO7239361			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: ng/mL				
geometric mean (geometric coefficient of variation)	23297 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW doses.

End point title	Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW doses.[5]

End point description:

PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW. Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 6. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results are only reported for the arms receiving the doses of RO7239361 as indicated.

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	6	18	
Units: hour				
median (full range (min-max))	28 (12 to 48)	24 (11 to 47)	30 (11 to 65)	

Statistical analyses

No statistical analyses for this end point

Secondary: Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW dose.

End point title	Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW dose.[6]

End point description:

PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. 9999=not calculable as data are reported for one subject.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results are only reported for the arm receiving the dose of RO7239361 as indicated.

End point values	Panel 3 and Expansion Panel RO7239361			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: hour				

median (full range (min-max))	44 (44 to 44)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-Time Curve from Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW doses.

End point title	Area Under the Concentration-Time Curve from Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW doses.[7]

End point description:

PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 8. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Results are only reported for the arms receiving the doses of RO7239361 as indicated.

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	6	18	
Units: ng•day/mL				
geometric mean (geometric coefficient of variation)	18676 (± 23)	51461 (± 18)	150609 (± 24)	

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-Time Curve from Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW dose.

End point title	Area Under the Concentration-Time Curve from Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW dose.[8]

End point description:

PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either

12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results are only reported for the arm receiving the dose of RO7239361 as indicated.

End point values	Panel 3 and Expansion Panel RO7239361			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: ng•day/mL				
geometric mean (geometric coefficient of variation)	151000 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: RO7239361 Trough Concentrations

End point title	RO7239361 Trough Concentrations[9]

End point description:

Trough concentrations of RO7239361 at different dose levels. Panel 1 = 4mg, Panel 2 = 12.5mg and 20mg, Panel 3 = 35mg, Expansion Panels = 35mg and 50mg. 9999=participant did not receive treatment at visit or sample was not taken; 99999=not evaluable as only data from one participant reported here Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results are only reported for arms receiving RO7239361.

End point values	Panel 1 RO7239361	Panel 2 RO7239361 12.5mg	Panel 2 RO7239361 20mg	Panel 3 RO7239361 35mg
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	7	1	7
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1 (n=7,6,0,5,12,1)	825.343 (± 23)	2115.951 (± 20)	9999 (± 9999)	6559.364 (± 26)

Day 15 (n=7,6,0,6,12,1)	1258.746 (± 35)	3697.590 (± 20)	9999 (± 9999)	9957.352 (± 34)
Day 22 (n=5,6,0,5,11,0)	1640.052 (± 15)	4220.280 (± 32)	9999 (± 9999)	12383.747 (± 30)
Day 29 (n=7,6,0,6,12,0)	2015.695 (± 32)	5107.668 (± 25)	9999 (± 9999)	14110.005 (± 34)
Day 84 (n=8,6,0,7,16,1)	2179.385 (± 26)	6484.502 (± 19)	9999 (± 9999)	19332.421 (± 20)
Day 168 (n=9,7,1,7,14,1)	2438.595 (± 16)	6100.315 (± 25)	6340.000 (± 99999)	19923.182 (± 41)

End point values	Expansion Panel RO7239361 35mg	Expansion Panel RO7239361 50mg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	16	1		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1 (n=7,6,0,5,12,1)	6017.978 (± 23)	5020.000 (± 99999)		
Day 15 (n=7,6,0,6,12,1)	9944.183 (± 24)	9980.000 (± 99999)		
Day 22 (n=5,6,0,5,11,0)	13215.188 (± 24)	999 (± 9999)		
Day 29 (n=7,6,0,6,12,0)	15094.455 (± 19)	9999 (± 9999)		
Day 84 (n=8,6,0,7,16,1)	18789.382 (± 18)	27800.000 (± 99999)		
Day 168 (n=9,7,1,7,14,1)	12580.299 (± 41)	26200.000 (± 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Positive Anti-RO7239361 Antibodies (ADA) Assessment, Double-Blind Phase

End point title	Percentage of Participants with Positive Anti-RO7239361 Antibodies (ADA) Assessment, Double-Blind Phase

End point description:

A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 8 through Week 24, baseline and on-study information represented in table.

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	7	6	19
Units: percentage of participants				
number (not applicable)				
Baseline (BL): ADA Positive	0	0	0	0
BL: ADA Negative	0	71.4	100.0	89.5
BL: Missing	100.0	28.6	0	10.5
On-treatment: ADA Positive	0	0	0	0
On-treatment: Persistent Positive	0	0	0	0
On-treatment: Only last sample Positive	0	0	0	0
On-treatment: Other Positive	0	0	0	0
On-treatment: ADA Negative	0	100.0	100.0	100.0
On-treatment: ADA Negative, BL Positive, No Boost	0	0	0	0
On-treatment: Missing	100.0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Positive Anti-RO7239361 Antibodies (ADA) Assessment up to Week 72

End point title	Percentage of Participants with Positive Anti-RO7239361 Antibodies (ADA) Assessment up to Week 72

End point description:

A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants is not included. Placebo participants in each arm moved on to RO7239361 upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 8 through Week 72, baseline and on-study information represented in table.

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	8	26	
Units: percentage of participants				
number (not applicable)				
Baseline (BL): ADA Positive	0	0	0	
BL: ADA Negative	77.8	87.5	88.5	
BL: Missing	22.2	12.5	11.5	
On-treatment: ADA Positive	0	0	3.8	
On-treatment: Persistent Positive	0	0	0	
On-treatment: Only last sample Positive	0	0	3.8	
On-treatment: Other Positive	0	0	0	
On-treatment: ADA Negative	100.0	100.0	96.2	
On-treatment: ADA Negative, BL Positive, No Boost	0	0	0	
On-treatment: Missing	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Free Myostatin in the Double-Blind Phase

End point title	Serum Concentration of Free Myostatin in the Double-Blind Phase

End point description:

Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. The pharmacodynamics (PD) data set included all available data from subjects for whom PD measurements were available at baseline and at least one other timepoint.

End point type	Secondary

End point timeframe:

Baseline through Week 24

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	7	6	19
Units: pg/mL				
arithmetic mean (standard deviation)				
Baseline (n=11,6,6,16)	1405.1 (± 809.57)	815.3 (± 155.14)	1391.3 (± 1084.97)	1121.8 (± 526.45)
Day 4 (n=8,5,4,18)	1356.6 (± 641.27)	421.4 (± 70.60)	321.3 (± 165.91)	58.3 (± 33.20)
Day 5 (n=9,7,6,18)	1438.2 (± 809.18)	446.6 (± 108.81)	357.8 (± 166.27)	66.1 (± 39.07)

Day 8 (n=10,6,6,19)	1014.2 (± 549.26)	522.7 (± 131.51)	479.2 (± 319.13)	206.8 (± 419.21)
Day 15 (n=11,7,6,19)	1266.9 (± 611.27)	478.4 (± 111.44)	280.8 (± 148.53)	54.8 (± 61.85)
Day 22 (n=11,7,6,17)	1317.1 (± 728.48)	382.4 (± 82.58)	284.8 (± 324.16)	35.3 (± 51.45)
Day 29 (n=11,7,6,17)	1214.0 (± 676.80)	372.3 (± 79.97)	179.0 (± 137.39)	24.8 (± 27.24)
Day 33 (n=11,7,6,18)	1141.4 (± 606.99)	291.1 (± 77.55)	115.7 (± 84.49)	24.3 (± 30.64)
Week 12 (n=10,6,4,18)	1366.5 (± 631.28)	307.8 (± 97.84)	110.8 (± 49.80)	16.2 (± 11.60)
Week 24 (n=11,7,6,18)	1194.0 (± 599.59)	297.1 (± 74.62)	160.8 (± 122.75)	23.4 (± 25.34)

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Inhibition of Free Myostatin in the Double-Blind Phase

End point title	Percent Inhibition of Free Myostatin in the Double-Blind Phase

End point description:

Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. The pharmacodynamics (PD) data set included all available data from subjects for whom PD measurements were available at baseline and at least one other timepoint.

End point type	Secondary

End point timeframe:

Baseline through Week 24

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	7	6	19
Units: percentage inhibition				
arithmetic mean (standard deviation)				
Day 4 (n=8,5,4,18)	0.595 (± 23.6952)	49.689 (± 11.7394)	73.533 (± 9.8637)	95.334 (± 2.4477)
Day 5 (n=9,7,6,18)	3.114 (± 20.3395)	46.506 (± 9.0917)	69.700 (± 10.3411)	94.545 (± 2.7608)
Day 8 (n=10,6,6,19)	23.917 (± 31.1378)	38.411 (± 7.0320)	62.524 (± 9.7074)	84.797 (± 22.1958)
Day 15 (n=11,7,6,19)	5.744 (± 18.6190)	40.763 (± 10.0071)	77.090 (± 6.2939)	96.488 (± 1.9665)
Day 22 (n=11,7,6,17)	5.561 (± 11.7425)	51.836 (± 9.3488)	81.693 (± 5.7392)	97.927 (± 1.1259)
Day 29 (n=11,7,6,17)	12.599 (± 16.1591)	52.926 (± 6.6001)	86.894 (± 2.9590)	98.202 (± 1.4590)
Day 33 (n=11,7,6,18)	15.662 (± 17.3640)	61.796 (± 4.5760)	91.557 (± 2.6444)	97.042 (± 5.4443)

Week 12 (n=10,6,4,18)	5.289 (± 15.5082)	60.254 (± 9.4283)	92.454 (± 1.7243)	98.415 (± 1.2882)
Week 24 (n=11,7,6,18)	9.910 (± 17.8109)	63.790 (± 5.7031)	88.392 (± 5.1669)	97.921 (± 2.2143)

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Drug-Myostatin Complex in the Double-Blind Phase

End point title	Serum Concentration of Drug-Myostatin Complex in the Double-Blind Phase

End point description:

Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. The pharmacodynamics (PD) data set included all available data from subjects for whom PD measurements were available at baseline and at least one other timepoint.

End point type	Secondary

End point timeframe:

Baseline through Week 24

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	7	6	19
Units: ng/mL				
arithmetic mean (standard deviation)				
Day 4 (n=9,3,4,7)	1.178 (± 1.8833)	5.070 (± 0.9456)	12.606 (± 5.7623)	14.696 (± 5.7926)
Day 5 (n=8,5,6,6)	2.119 (± 2.9826)	5.845 (± 2.5725)	14.856 (± 7.6131)	17.308 (± 7.5955)
Day 8 (n=10,6,6,7)	4.924 (± 12.9975)	7.041 (± 2.3470)	19.906 (± 9.8664)	21.609 (± 11.0880)
Day 15 (n=11,7,6,7)	0.613 (± 0.2102)	14.067 (± 7.1096)	29.229 (± 10.4929)	45.289 (± 18.7600)
Day 22 (n=10,7,6,6)	1.326 (± 1.3410)	11.985 (± 4.8243)	36.811 (± 26.8560)	52.841 (± 21.5542)
Day 29 (n=11,7,6,7)	1.593 (± 3.1007)	15.735 (± 4.2010)	43.236 (± 34.0300)	67.255 (± 27.9376)
Day 33 (n=9,7,4,7)	1.157 (± 1.0036)	18.542 (± 3.9874)	46.279 (± 24.1457)	77.142 (± 32.4153)
Week 12 (n=10,6,5,14)	7.082 (± 15.2289)	28.556 (± 22.7890)	79.555 (± 17.2126)	88.402 (± 29.8080)
Week 24 (n=8,7,5,7)	3.589 (± 7.8108)	25.997 (± 6.4384)	83.262 (± 64.2281)	101.406 (± 45.4197)

Statistical analyses

No statistical analyses for this end point

Secondary: Fold Change from Baseline in Contractile Versus Non-contractile Content for Muscles in the Right Thigh in the Double-Blind Phase

End point title	Fold Change from Baseline in Contractile Versus Non-contractile Content for Muscles in the Right Thigh in the Double-Blind Phase[10]

End point description:

Ratio of contractile vs non-contractile content is contractile content / non-contractile content. Fold change from baseline of the ratio is defined as the ratio of fold change from baseline of contractile content vs fold change from baseline of non-contractile content. Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Baseline through Week 24

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results for Panel 3 and the Expansion Panel were reported separately by Subject analysis sets.

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	11	7	6	6
Units: Fold Change				
arithmetic mean (standard error)				
W12: ADDUCTOR LONGUS (n=7,3,5,4,11)	1.04 (± 0.291)	0.95 (± 0.088)	1.16 (± 0.330)	2.27 (± 1.122)
W12: ADDUCTOR MAGNUS (n=8,5,4,5,11)	0.69 (± 0.104)	0.88 (± 0.283)	1.12 (± 0.281)	0.93 (± 0.255)
W12: BICEPS FEMORIS LONG (n=7,4,6,4,11)	0.78 (± 0.221)	0.94 (± 0.304)	1.57 (± 0.556)	1.10 (± 0.280)
W12: BICEPS FEMORIS SHORT (n=7,4,4,5,11)	0.92 (± 0.269)	2.77 (± 1.144)	2.03 (± 1.564)	0.79 (± 0.162)
W12: GRACILIS (n=6,4,4,4,11)	1.13 (± 0.318)	7.57 (± 5.372)	0.98 (± 0.176)	3.41 (± 2.474)
W12:RECTUS FEMORIS (n=7,6,6,4,11)	0.74 (± 0.185)	0.55 (± 0.134)	4.49 (± 2.729)	0.99 (± 0.345)
W12: SARTORIUS (n=6,4,5,4,10)	1.78 (± 0.771)	0.69 (± 0.307)	1.04 (± 0.443)	0.90 (± 0.396)
W12: SEMIMEMBRANOSUS (n=8,5,6,6,13)	0.82 (± 0.230)	0.82 (± 0.284)	1.47 (± 0.777)	0.86 (± 0.276)
W12: SEMITENDINOSUS (n=8,4,5,4,11)	0.78 (± 0.262)	2.95 (± 1.016)	1.31 (± 0.260)	1.42 (± 0.317)
W12: VASTUS INTERMEDIUS (n=7,3,4,4,10)	2.59 (± 1.749)	1.11 (± 0.292)	0.62 (± 0.258)	0.86 (± 0.157)
W12: VASTUS LATERALIS (n=7,5,6,5,12)	0.66 (± 0.160)	0.89 (± 0.272)	1.10 (± 0.333)	1.78 (± 0.455)
W12: VASTUS MEDIALIS (n=6,4,6,4,12)	1.08 (± 0.269)	1.26 (± 0.112)	2.97 (± 1.981)	0.85 (± 0.280)
W24: ADDUCTOR LONGUS (n=9,4,4,5,11)	0.81 (± 0.290)	1.14 (± 0.269)	1.11 (± 0.471)	1.36 (± 0.718)
W24: ADDUCTOR MAGNUS (n=10,6,4,5,11)	0.66 (± 0.112)	0.94 (± 0.296)	0.59 (± 0.144)	1.61 (± 0.697)
W24: BICEPS FEMORIS LONG (n=8,5,5,4,12)	1.07 (± 0.511)	1.13 (± 0.315)	1.00 (± 0.349)	1.29 (± 0.238)

W24: BICEPS FEMORIS SHORT (n=7,5,4,5,12)	0.91 (± 0.195)	2.24 (± 1.027)	2.15 (± 1.003)	1.24 (± 0.411)
W24: GRACILIS (n=9,3,3,4,9)	1.43 (± 0.686)	3.03 (± 2.564)	1.37 (± 0.465)	1.45 (± 0.748)
W24:RECTUS FEMORIS (n=8,6,5,4,11)	0.94 (± 0.256)	0.84 (± 0.220)	7.43 (± 6.216)	0.80 (± 0.262)
W24: SARTORIUS (n=7,5,4,4,10)	1.90 (± 0.872)	0.73 (± 0.207)	0.78 (± 0.375)	3.24 (± 1.850)
W24: SEMIMEMBRANOSUS (n=10,6,5,4,12)	0.66 (± 0.126)	0.90 (± 0.361)	0.72 (± 0.157)	0.94 (± 0.250)
W24: SEMITENDINOSUS (n=9,5,4,6,11)	0.56 (± 0.119)	1.59 (± 0.520)	1.43 (± 0.524)	1.04 (± 0.254)
W24: VASTUS INTERMEDIUS (n=7,4,3,4,10)	0.95 (± 0.412)	1.47 (± 0.446)	0.63 (± 0.355)	0.96 (± 0.095)
W24: VASTUS LATERALIS (n=10,5,5,4,12)	0.78 (± 0.159)	1.88 (± 0.905)	1.45 (± 0.596)	1.43 (± 0.256)
W24: VASTUS MEDIALIS (n=8,5,4,4,12)	2.14 (± 0.889)	5.16 (± 3.580)	6.01 (± 5.478)	1.29 (± 0.474)

End point values	Expansion Panel RO7239361			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: Fold Change				
arithmetic mean (standard error)				
W12: ADDUCTOR LONGUS (n=7,3,5,4,11)	2.36 (± 0.875)			
W12: ADDUCTOR MAGNUS (n=8,5,4,5,11)	1.04 (± 0.101)			
W12: BICEPS FEMORIS LONG (n=7,4,6,4,11)	1.26 (± 0.237)			
W12: BICEPS FEMORIS SHORT (n=7,4,4,5,11)	1.31 (± 0.301)			
W12: GRACILIS (n=6,4,4,4,11)	5.42 (± 3.871)			
W12:RECTUS FEMORIS (n=7,6,6,4,11)	2.02 (± 0.764)			
W12: SARTORIUS (n=6,4,5,4,10)	2.00 (± 0.683)			
W12: SEMIMEMBRANOSUS (n=8,5,6,6,13)	1.31 (± 0.194)			
W12: SEMITENDINOSUS (n=8,4,5,4,11)	1.17 (± 0.160)			
W12: VASTUS INTERMEDIUS (n=7,3,4,4,10)	1.64 (± 0.377)			
W12: VASTUS LATERALIS (n=7,5,6,5,12)	1.70 (± 0.334)			
W12: VASTUS MEDIALIS (n=6,4,6,4,12)	5.96 (± 3.376)			
W24: ADDUCTOR LONGUS (n=9,4,4,5,11)	2.41 (± 0.813)			
W24: ADDUCTOR MAGNUS (n=10,6,4,5,11)	1.14 (± 0.146)			
W24: BICEPS FEMORIS LONG (n=8,5,5,4,12)	2.10 (± 1.044)			
W24: BICEPS FEMORIS SHORT (n=7,5,4,5,12)	2.02 (± 0.416)			
W24: GRACILIS (n=9,3,3,4,9)	5.17 (± 3.540)			
W24:RECTUS FEMORIS (n=8,6,5,4,11)	3.01 (± 1.612)			
W24: SARTORIUS (n=7,5,4,4,10)	2.45 (± 0.842)			
W24: SEMIMEMBRANOSUS (n=10,6,5,4,12)	1.39 (± 0.256)			
W24: SEMITENDINOSUS (n=9,5,4,6,11)	1.22 (± 0.221)			

W24: VASTUS INTERMEDIUS (n=7,4,3,4,10)	1.47 (± 0.318)			
W24: VASTUS LATERALIS (n=10,5,5,4,12)	2.03 (± 0.484)			
W24: VASTUS MEDIALIS (n=8,5,4,4,12)	3.50 (± 1.390)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Thigh Muscle Maximal Cross Sectional Area (CSAmax) in the Double-Blind Phase

End point title	Change from Baseline in Thigh Muscle Maximal Cross Sectional Area (CSAmax) in the Double-Blind Phase[11]

End point description:

Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Baseline through Week 24

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Results for Panel 3 and the Expansion Panel were reported separately by Subject analysis sets.

End point values	Placebo	Panel 1 RO7239361	Panel 2 RO7239361	Expansion Panel RO7239361
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	11	7	6	13
Units: Percentage Change				
arithmetic mean (standard error)				
W12: ADDUCTOR LONGUS (n=9,6,6,6,12)	7.29 (± 16.559)	8.31 (± 11.767)	5.85 (± 11.074)	29.98 (± 8.530)
W12: ADDUCTOR MAGNUS (n=9,6,6,6,12)	31.01 (± 24.708)	24.12 (± 11.804)	-3.73 (± 29.037)	4.01 (± 54.787)
W12: BICEPS FEMORIS LONG (n=9,6,6,6,12)	34.24 (± 18.328)	33.43 (± 35.009)	16.72 (± 17.806)	23.93 (± 11.289)
W12: BICEPS FEMORIS SHORT (n=9,6,6,6,12)	14.10 (± 7.724)	7.45 (± 11.592)	2.69 (± 13.733)	9.84 (± 3.882)
W12: GRACILIS (n=9,6,6,6,12)	20.14 (± 15.489)	43.00 (± 28.539)	15.28 (± 8.693)	23.22 (± 5.440)
W12:RECTUS FEMORIS (n=9,6,6,6,12)	-7.86 (± 14.391)	10.33 (± 11.927)	-3.56 (± 14.175)	16.01 (± 9.888)
W12: SARTORIUS (n=9,6,6,6,12)	11.26 (± 6.584)	6.59 (± 11.952)	-0.85 (± 6.383)	18.20 (± 5.519)
W12: SEMIMEMBRANOSUS (n=9,6,6,6,12)	39.11 (± 15.041)	32.57 (± 19.133)	16.56 (± 19.998)	31.01 (± 10.564)
W12: SEMITENDINOSUS (n=9,6,6,6,12)	25.03 (± 9.409)	-1.24 (± 10.973)	33.00 (± 26.730)	40.10 (± 10.180)
W12: VASTUS INTERMEDIUS (n=9,6,6,6,12)	10.47 (± 12.160)	23.35 (± 12.704)	-52.03 (± 71.421)	10.44 (± 7.344)

W12: VASTUS LATERALIS (n=9,6,6,6,12)	31.47 (± 39.343)	38.32 (± 19.570)	14.08 (± 27.902)	22.73 (± 15.138)
W12: VASTUS MEDIALIS (n=9,6,6,6,12)	-17.89 (± 19.358)	15.65 (± 8.463)	-11.60 (± 15.849)	17.89 (± 6.788)
W24: ADDUCTOR LONGUS (n=11,7,5,6,12)	11.69 (± 15.626)	23.41 (± 13.199)	12.81 (± 16.393)	44.12 (± 13.323)
W24: ADDUCTOR MAGNUS (n=11,7,5,6,12)	34.17 (± 24.918)	21.90 (± 12.345)	-6.71 (± 37.311)	4.41 (± 52.393)
W24: BICEPS FEMORIS LONG (n=11,7,5,6,12)	39.21 (± 19.760)	42.84 (± 22.086)	-5.32 (± 29.140)	31.33 (± 13.370)
W24: BICEPS FEMORIS SHORT (n=11,7,5,6,12)	20.09 (± 9.818)	11.83 (± 13.013)	-0.44 (± 16.183)	18.60 (± 5.394)
W24: GRACILIS (n=11,7,5,6,12)	8.14 (± 7.148)	18.72 (± 16.757)	11.21 (± 5.461)	40.15 (± 8.382)
W24:RECTUS FEMORIS (n=11,7,5,6,12)	8.97 (± 10.214)	7.68 (± 13.082)	-10.01 (± 16.121)	38.40 (± 14.293)
W24: SARTORIUS (n=11,7,5,6,12)	10.75 (± 7.136)	0.81 (± 8.143)	-14.18 (± 9.481)	25.51 (± 6.404)
W24: SEMIMEMBRANOSUS (n=11,7,5,6,12)	45.83 (± 14.896)	30.01 (± 18.631)	-11.48 (± 24.468)	49.49 (± 12.011)
W24: SEMITENDINOSUS (n=11,7,5,6,12)	32.00 (± 16.102)	36.17 (± 23.285)	24.16 (± 23.403)	62.55 (± 11.073)
W24: VASTUS INTERMEDIUS (n=11,7,5,6,12)	14.86 (± 15.072)	43.01 (± 11.506)	-68.05 (± 86.362)	22.55 (± 8.284)
W24: VASTUS LATERALIS (n=11,7,5,6,12)	12.95 (± 35.465)	47.79 (± 26.178)	32.64 (± 30.136)	46.87 (± 20.919)
W24: VASTUS MEDIALIS (n=11,7,5,6,12)	-9.09 (± 11.856)	9.82 (± 6.965)	-13.74 (± 29.664)	23.94 (± 11.321)

End point values	Panel 3 RO7239361			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: Percentage Change				
arithmetic mean (standard error)				
W12: ADDUCTOR LONGUS (n=9,6,6,6,12)	14.61 (± 9.755)			
W12: ADDUCTOR MAGNUS (n=9,6,6,6,12)	53.20 (± 25.328)			
W12: BICEPS FEMORIS LONG (n=9,6,6,6,12)	19.22 (± 9.802)			
W12: BICEPS FEMORIS SHORT (n=9,6,6,6,12)	18.68 (± 7.479)			
W12: GRACILIS (n=9,6,6,6,12)	27.02 (± 5.686)			
W12:RECTUS FEMORIS (n=9,6,6,6,12)	34.91 (± 6.037)			
W12: SARTORIUS (n=9,6,6,6,12)	10.81 (± 11.017)			
W12: SEMIMEMBRANOSUS (n=9,6,6,6,12)	46.70 (± 16.480)			
W12: SEMITENDINOSUS (n=9,6,6,6,12)	36.69 (± 14.802)			
W12: VASTUS INTERMEDIUS (n=9,6,6,6,12)	-0.81 (± 19.353)			
W12: VASTUS LATERALIS (n=9,6,6,6,12)	57.86 (± 34.026)			

W12: VASTUS MEDIALIS (n=9,6,6,6,12)	21.14 (± 9.746)			
W24: ADDUCTOR LONGUS (n=11,7,5,6,12)	17.15 (± 15.484)			
W24: ADDUCTOR MAGNUS (n=11,7,5,6,12)	45.05 (± 27.520)			
W24: BICEPS FEMORIS LONG (n=11,7,5,6,12)	33.70 (± 12.073)			
W24: BICEPS FEMORIS SHORT (n=11,7,5,6,12)	30.01 (± 13.494)			
W24: GRACILIS (n=11,7,5,6,12)	48.95 (± 17.064)			
W24:RECTUS FEMORIS (n=11,7,5,6,12)	55.65 (± 27.535)			
W24: SARTORIUS (n=11,7,5,6,12)	16.63 (± 4.476)			
W24: SEMIMEMBRANOSUS (n=11,7,5,6,12)	61.03 (± 25.524)			
W24: SEMITENDINOSUS (n=11,7,5,6,12)	73.68 (± 17.594)			
W24: VASTUS INTERMEDIUS (n=11,7,5,6,12)	41.63 (± 34.926)			
W24: VASTUS LATERALIS (n=11,7,5,6,12)	45.41 (± 43.774)			
W24: VASTUS MEDIALIS (n=11,7,5,6,12)	10.46 (± 12.093)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Positive Anti-RO7239361 Antibodies (ADA) Assessment, Whole Study

End point title	Percentage of Participants with Positive Anti-RO7239361 Antibodies (ADA) Assessment, Whole Study

End point description:

A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361.

End point type	Secondary

End point timeframe:

Day 8 through Week 228, baseline and on-study information represented in table.

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	8	26	
Units: percentage of participants				
number (not applicable)				
Baseline (BL): ADA Positive	0	0	0	
BL: ADA Negative	100.0	87.5	92.3	
BL: Missing	0	12.5	7.7	
On-treatment: ADA Positive	0	0	3.8	
On-treatment: Persistent Positive	0	0	0	
On-treatment: Only last sample Positive	0	0	0	
On-treatment: Other Positive	0	0	3.8	
On-treatment: ADA Negative	100.0	100.0	96.2	
On-treatment: ADA Negative, BL Positive, No Boost	0	0	0	
On-treatment: Missing	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Free Myostatin, Whole Study

End point title	Serum Concentration of Free Myostatin, Whole Study

End point description:

Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Panel 1 received 4 mg RO7239361; Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. 9999=not calculable as data are reported for one subject. 99999=no data available The pharmacodynamics (PD) data set included all available data from subjects for whom PD measurements were available at baseline and at least one other timepoint. The Whole Study set reported here includes data from RO7239361-treated participants only. 9999=not calculable as data are reported for one subject. 99999=no data available

End point type	Secondary

End point timeframe:

Baseline through Week 252

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	8	25	
Units: pg/mL				
arithmetic mean (standard deviation)				

Baseline (n=8,8,23)	986.8 (± 363.69)	1358.4 (± 964.47)	1159.3 (± 601.29)	
Day 4 (n=5,4,18)	421.4 (± 70.60)	321.3 (± 165.91)	58.3 (± 33.20)	
Day 5 (n=7,6,18)	446.6 (± 108.81)	357.8 (± 166.27)	66.1 (± 39.07)	
Day 8 (n=6,6,19)	522.7 (± 131.51)	479.2 (± 319.13)	206.8 (± 419.21)	
Day 15 (n=7,6,19)	478.4 (± 111.44)	280.8 (± 148.53)	54.8 (± 61.85)	
Day 22 (n=7,6,17)	382.4 (± 82.58)	284.8 (± 324.16)	35.3 (± 51.45)	
Day 29 (n=7,6,17)	372.3 (± 79.97)	179.0 (± 137.39)	24.8 (± 27.24)	
Day 33 (n=7,6,18)	291.1 (± 77.55)	115.7 (± 84.49)	24.3 (± 30.64)	
Week 12 (n=8,6,25)	394.0 (± 179.78)	115.0 (± 62.23)	18.1 (± 13.37)	
Week 24 (n=9,8,24)	357.9 (± 137.56)	139.1 (± 111.63)	23.0 (± 23.68)	
Week 25 (n=6,6,17)	331.0 (± 116.78)	154.5 (± 115.21)	22.8 (± 18.48)	
Week 36 (n=9,7,16)	340.3 (± 98.24)	81.4 (± 36.00)	21.1 (± 22.03)	
Week 48 (n=9,7,16)	401.3 (± 233.76)	79.0 (± 37.85)	18.6 (± 12.11)	
Week 60 (n=7,5,9)	284.6 (± 96.92)	90.4 (± 39.30)	36.3 (± 54.13)	
Week 72 (n=5,4,3)	326.8 (± 151.29)	132.0 (± 146.37)	205.7 (± 321.58)	
Week 84 (n=4,2,15)	534.0 (± 260.31)	74.2 (± 13.58)	115.6 (± 146.44)	
Week 108 (n=9,5,16)	320.9 (± 222.10)	84.4 (± 61.19)	40.2 (± 42.70)	
Week 132 (n=8,7,21)	283.5 (± 103.73)	71.0 (± 40.02)	40.2 (± 38.26)	
Week 144 (n=0,1,0)	99999 (± 99999)	95.2 (± 9999)	99999 (± 99999)	
Week 156 (n=7,4,8)	208.7 (± 64.52)	48.9 (± 22.42)	20.0 (± 0.00)	
Week 180 (n=2,0,0)	212.5 (± 146.37)	99999 (± 99999)	99999 (± 99999)	
Week 252 (n=0,1,0)	99999 (± 99999)	20.0 (± 9999)	99999 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Inhibition of Free Myostatin, Whole Study

End point title	Percent Inhibition of Free Myostatin, Whole Study

End point description:

Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg

(weight >45 kg) RO7239361. The pharmacodynamics (PD) data set included all available data from subjects for whom PD measurements were available at baseline and at least one other timepoint. The Whole Study set reported here includes data from RO7239361-treated participants only. 9999=not calculable as data are reported for one subject. 99999=no data available

End point type	Secondary

End point timeframe:

Baseline through Week 252

End point values	Panel 1 RO7239361	Panel 2 RO7239361	Panel 3 and Expansion Panel RO7239361	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	8	22	
Units: percentage inhibition				
arithmetic mean (standard deviation)				
Day 4 (n=4,4,15)	49.689 (± 11.7394)	73.533 (± 9.8637)	95.334 (± 2.4477)	
Day 5 (n=6,6,16)	46.506 (± 9.0917)	69.700 (± 10.3411)	94.545 (± 2.7608)	
Day 8 (n=5,6,16)	38.411 (± 7.0320)	62.524 (± 9.7074)	84.797 (± 22.1958)	
Day 15 (n=6,6,16)	40.763 (± 10.0071)	77.090 (± 6.2939)	96.488 (± 1.9665)	
Day 22 (n=6,6,15)	51.836 (± 9.3488)	81.693 (± 5.7392)	97.927 (± 1.1259)	
Day 29 (n=6,6,15)	52.926 (± 6.6001)	86.894 (± 2.9590)	98.202 (± 1.4590)	
Day 33 (n=6,6,15)	61.796 (± 4.5760)	91.557 (± 2.6444)	97.042 (± 5.4443)	
Week 12 (n=7,6,22)	58.934 (± 8.7345)	92.025 (± 2.0548)	98.208 (± 1.5605)	
Week 24 n=8,8,21)	63.199 (± 5.3419)	89.664 (± 5.0245)	98.009 (± 1.8677)	
Week 25 (n=5,6,16)	62.446 (± 7.0668)	88.689 (± 4.8868)	97.974 (± 1.8259)	
Week 36 (n=8,7,15)	64.103 (± 5.3774)	92.057 (± 2.6300)	98.470 (± 0.8410)	
Week 48 (n=8,7,14)	58.161 (± 15.7101)	92.237 (± 3.4952)	98.036 (± 1.4516)	
Week 60 (n=6,5,7)	66.280 (± 8.4684)	90.974 (± 2.1780)	97.177 (± 2.8783)	
Week 72 (n=4,4,3)	65.956 (± 8.2066)	92.536 (± 2.4445)	79.193 (± 31.9504)	
Week 84 (n=4,2,13)	54.990 (± 1.0397)	92.328 (± 5.7945)	89.744 (± 13.0990)	
Week 108 (n=8,5,14)	70.498 (± 15.2905)	92.412 (± 3.3662)	95.884 (± 3.5214)	
Week 132 (n=8,7,18)	71.129 (± 4.9576)	92.935 (± 3.8121)	96.713 (± 2.4278)	
Week 144 (n=0,1,0)	99999 (± 99999)	94.732 (± 9999)	99999 (± 99999)	
Week 156 (n=6,4,6)	74.712 (± 5.7764)	94.881 (± 1.3726)	98.183 (± 0.8086)	
Week 180 (n=2,0,0)	75.374 (± 9.5968)	99999 (± 99999)	99999 (± 99999)	

Week 252 (n=0,1,0)	99999 (± 99999)	96.283 (± 9999)	99999 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Drug-Myostatin Complex, Whole Study

End point title	Serum Concentration of Drug-Myostatin Complex, Whole Study

End point description:

Participants in the Placebo arm received placebo during the double-blind (DB) period (up to Week 24) and received RO7239361 during the open label (OL) phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight >45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight >45 kg) RO7239361. The pharmacodynamics (PD) data set included all available data from subjects for whom PD measurements were available at baseline and at least one other timepoint. 9999=not calculable as data are reported for one subject. 99999=no data available

End point type	Secondary

End point timeframe:

Baseline through Week 252

End point values	Placebo, then RO7239361	Panel 1 RO7239361 Whole Study	Panel 2 RO7239361 Whole Study	Panel 3 and Expansion Panel RO7239361 Whole Study
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	11	7	6	18
Units: ng/mL				
arithmetic mean (standard deviation)				
Day 4 (n=9,3,4,7)	1.178 (± 1.8833)	5.070 (± 0.9456)	12.606 (± 5.7623)	14.696 (± 5.7926)
Day 5 (n=8,5,6,6)	2.119 (± 2.9826)	5.845 (± 2.5725)	14.856 (± 7.6131)	17.308 (± 7.5955)
Day 8 (n=10,6,6,7)	4.924 (± 12.9975)	7.041 (± 2.3470)	19.906 (± 9.8664)	21.609 (± 11.0880)
Day 15 (n=11,7,6,7)	0.613 (± 0.2102)	14.067 (± 7.1096)	29.229 (± 10.4929)	45.289 (± 18.7600)
Day 22 (n=10,7,6,6)	1.326 (± 1.3410)	11.985 (± 4.8243)	36.811 (± 26.8560)	52.841 (± 21.5542)
Day 29 (n=11,7,6,7)	1.593 (± 3.1007)	15.735 (± 4.2010)	43.236 (± 34.0300)	67.255 (± 27.9376)
Day 33 (n=9,7,4,7)	1.157 (± 1.0036)	18.542 (± 3.9874)	46.279 (± 24.1457)	77.142 (± 32.4153)
Week 12 (n=10,6,5,14)	7.082 (± 15.2289)	28.556 (± 22.7890)	79.555 (± 17.2126)	88.402 (± 29.8080)
Week 24 (end of DB period) (n=8,7,5,7)	3.589 (± 7.8108)	25.997 (± 6.4384)	83.262 (± 64.2281)	101.406 (± 45.4197)
Week 25 (Week 1 OL) (n=7,7,5,8)	3.186 (± 6.9734)	31.963 (± 8.0240)	77.926 (± 56.9987)	102.211 (± 40.2284)

Week 36 (Week 12 OL) (n=10,6,5,14)	95.788 (± 88.1521)	22.584 (± 8.6839)	57.164 (± 25.8284)	101.234 (± 42.0902)
Week 48 (Week 24 OL) (n=9,7,0,18)	90.593 (± 73.7102)	27.461 (± 7.2306)	99999 (± 99999)	103.657 (± 45.8802)
Week 60 (Week 36 OL) (n=5,7,5,3)	63.358 (± 37.5591)	41.779 (± 34.2407)	89.712 (± 38.9214)	67.163 (± 8.4904)
Week 72 (Week 48 OL) (n=5,5,1,4)	92.086 (± 68.5222)	26.740 (± 3.0256)	0.550 (± 9999)	102.025 (± 31.4717)
Week 84 (Week 60 OL) (n=6,2,0,16)	146.950 (± 131.3706)	27.110 (± 3.2527)	99999 (± 99999)	117.719 (± 41.1143)
Week 108 (Week 84 OL) (n=10,7,5,18)	122.610 (± 87.1911)	36.014 (± 10.9338)	66.020 (± 7.2878)	114.806 (± 32.7432)
Week 132 (Week 108 OL) (n=9,6,5,18)	95.811 (± 48.1440)	32.133 (± 8.2848)	75.040 (± 14.3015)	107.378 (± 37.8814)
Week 144 (Week 120 OL) (n=0,1,0,0)	99999 (± 99999)	25.600 (± 9999)	99999 (± 99999)	99999 (± 99999)
Week 156 (Week 132 OL) (n=7,7,4,18)	95.529 (± 48.0065)	30.186 (± 7.0053)	69.325 (± 17.7064)	108.100 (± 35.5833)
Week 156 (Week 132 OL: Day 1 PFS) (n=2,0,0,0)	64.400 (± 0.5657)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)
Week 156 (Week 132 OL: Week 12 PFS) (n=1,0,0,6)	152.000 (± 9999)	99999 (± 99999)	99999 (± 99999)	125.583 (± 44.4144)
Week 168 (Week 144 OL: Day 1 PFS) (n=3,0,3,3)	105.700 (± 54.5772)	99999 (± 99999)	70.100 (± 25.1213)	122.633 (± 91.2542)
Week 168 (Week 144 OL: Day 8 PFS) (n=0,0,0,1)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	119.000 (± 9999)
Week 168 (Week 144 OL: Week 12 PFS) (n=0,0,1,0)	99999 (± 99999)	99999 (± 99999)	94.900 (± 9999)	99999 (± 99999)
Week 180 (Week 156 OL) (n=3,7,2,0)	45.933 (± 28.3161)	25.589 (± 12.2478)	103.300 (± 16.5463)	99999 (± 99999)
Week 180 (Week 156 OL: Week 12 PFS) (n=0,1,0,0)	99999 (± 99999)	62.600 (± 9999)	99999 (± 99999)	99999 (± 99999)
Week 192 (Week 168 OL: Day 1 PFS) (n=0,1,0,0)	99999 (± 99999)	18.000 (± 9999)	999999 (± 99999)	99999 (± 99999)
Week 192 (Week 168 OL: Day 45 PFS) (n=0,1,0,0)	99999 (± 999999)	80.400 (± 9999)	99999 (± 99999)	99999 (± 99999)
Week 252 (Week 228 OL) (n=10,5,3,17)	96.770 (± 61.6084)	52.680 (± 20.8619)	87.900 (± 38.5763)	106.071 (± 48.6434)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 252

Adverse event reporting additional description:

Upon completion of the double-blind phase, participants who were receiving placebo switched to the equivalent RO7239361 panel dose for the open label phase. All adverse event data is represented according to the phase (double-blind or open-label) during which the participant experienced the event.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	Placebo Double-Blind

Reporting group description:

Placebo subcutaneous injections on specified days during the double-blind period.

Reporting group title	Panel 1 RO7239361 Double-Blind

Reporting group description:

RO7239361 subcutaneous injections on specified days during the double-blind period.

Reporting group title	Panel 2 RO7239361 Double-Blind

Reporting group description:

RO7239361 subcutaneous injections on specified days during the double-blind period.

Reporting group title	Panel 3 and Expansion Panel RO7239361 Double-Blind

Reporting group description:

RO7239361 subcutaneous injections on specified days during the double-blind period.

Reporting group title	Panel 1 RO7239361 Open-Label

Reporting group description:

RO7239361 subcutaneous injections on specified days during the open-label period.

Reporting group title	Panel 2 RO7239361 Open-Label

Reporting group description:

RO7239361 subcutaneous injections on specified days during the open-label period.

Reporting group title	Panel 3 and Expansion Panel RO7239361 Open-Label

Reporting group description:

RO7239361 subcutaneous injections on specified days during the open-label period.

Serious adverse events	Placebo Double-Blind	Panel 1 RO7239361 Double-Blind	Panel 2 RO7239361 Double-Blind
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
FEMUR FRACTURE			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKULL FRACTURE			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
CONVERSION DISORDER			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
RHABDOMYOLYSIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
INFLUENZA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
APPENDICITIS PERFORATED			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Panel 3 and Expansion Panel RO7239361 Double-Blind	Panel 1 RO7239361 Open-Label	Panel 2 RO7239361 Open-Label
Total subjects affected by serious adverse events			

subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	2 / 8 (25.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
FEMUR FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKULL FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
CONVERSION DISORDER			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
RHABDOMYOLYSIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
INFLUENZA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
APPENDICITIS PERFORATED			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Panel 3 and Expansion Panel RO7239361 Open-Label		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 26 (3.85%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
FEMUR FRACTURE			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SKULL FRACTURE			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
CONVERSION DISORDER			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
RHABDOMYOLYSIS			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
INFLUENZA			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

APPENDICITIS PERFORATED			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo Double-Blind	Panel 1 RO7239361 Double-Blind	Panel 2 RO7239361 Double-Blind
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 11 (81.82%)	5 / 7 (71.43%)	6 / 6 (100.00%)
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HAEMATOMA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	3 / 11 (27.27%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	3	0	1
INJECTION SITE BRUISING			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
INJECTION SITE RASH			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	1 / 6 (16.67%)
occurrences (all)	1	1	9
CHILLS			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE HAEMORRHAGE			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE IRRITATION			

subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	5	0
PERIPHERAL SWELLING			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE PAIN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FATIGUE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE DISCOMFORT			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE ERYTHEMA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE SWELLING			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE REACTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE OEDEMA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE PRURITUS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
SEASONAL ALLERGY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Reproductive system and breast disorders			
TESTICULAR TORSION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	2 / 11 (18.18%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
EPISTAXIS			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
NASAL CONGESTION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
PRODUCTIVE COUGH			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
ASTHMA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HICCUPS			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
NASAL DISCHARGE DISCOLOURATION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
PARANASAL SINUS HYPERSECRETION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RHINORRHOEA			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BRONCHOSPASM			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LOWER RESPIRATORY TRACT CONGESTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PLEURAL EFFUSION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RHINITIS ALLERGIC			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SLEEP APNOEA SYNDROME			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
BRUXISM			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ANGER			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ENURESIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
LYMPH NODE PALPABLE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			

ARTHROPOD BITE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
CONTUSION			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
FALL			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
LIGAMENT SPRAIN			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
SKIN ABRASION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
EYELID CONTUSION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
FOOT FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
POST-TRAUMATIC PAIN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
THERMAL BURN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EYE CONTUSION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HEAD INJURY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
UPPER LIMB FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

CORNEAL ABRASION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FIBULA FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
JOINT INJURY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LIMB INJURY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PROCEDURAL PAIN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN LACERATION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SOFT TISSUE INJURY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SUNBURN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TIBIA FRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			

DERMOID CYST			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
SINUS TACHYCARDIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CARDIOMYOPATHY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LEFT VENTRICULAR DYSFUNCTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MYOCARDIAL FIBROSIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
HEADACHE			
subjects affected / exposed	2 / 11 (18.18%)	2 / 7 (28.57%)	1 / 6 (16.67%)
occurrences (all)	2	2	1
DIZZINESS			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
MOTOR DYSFUNCTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SINUS HEADACHE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
EAR PAIN			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
TYMPANIC MEMBRANE PERFORATION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

TYMPANIC MEMBRANE HYPERAEMIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
DIARRHOEA			
subjects affected / exposed	2 / 11 (18.18%)	1 / 7 (14.29%)	1 / 6 (16.67%)
occurrences (all)	4	1	1
VOMITING			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
ABDOMINAL PAIN			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
ABDOMINAL DISTENSION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BREATH ODOUR			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DYSPEPSIA			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
LIP SWELLING			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
MOUTH ULCERATION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
NAUSEA			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
GASTRIC ULCER			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMATOCHEZIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MALPOSITIONED TEETH			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOUS STOOLS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
RASH			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	4
DERMATITIS CONTACT			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

SKIN ULCER			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
DRY SKIN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ERYTHEMA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INGROWING NAIL			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ACNE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COLD SWEAT			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EPHELIDES			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LIVEDO RETICULARIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
POLYURIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEPHROLITHIASIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			

ADRENAL INSUFFICIENCY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CUSHINGOID			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DELAYED PUBERTY			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	2 / 6 (33.33%)
occurrences (all)	0	1	2
BACK PAIN			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
JOINT SWELLING			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
MUSCLE SPASMS			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
NECK PAIN			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ARTHRALGIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
JOINT CONTRACTURE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OSTEOPOROSIS			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COCCYDYNIA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COSTOCHONDRITIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INTERVERTEBRAL DISC COMPRESSION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCLE TIGHTNESS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAIN IN JAW			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SYNOVIAL CYST			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 11 (18.18%)	0 / 7 (0.00%)	2 / 6 (33.33%)
occurrences (all)	3	0	2
NASOPHARYNGITIS			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	1 / 6 (16.67%)
occurrences (all)	1	2	1
EAR INFECTION			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
PHARYNGITIS STREPTOCOCCAL			

subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
NAIL INFECTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PHARYNGITIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ABSCESS ORAL			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BODY TINEA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CONJUNCTIVITIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FUNGAL SKIN INFECTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LABYRINTHITIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ONYCHOMYCOSIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA MYCOPLASMAL			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SCARLET FEVER			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN CANDIDA			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
STAPHYLOCOCCAL SKIN INFECTION			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TOOTH ABSCESS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VIRAL RHINITIS			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Non-serious adverse events	Panel 3 and Expansion Panel RO7239361 Double-Blind	Panel 1 RO7239361 Open-Label	Panel 2 RO7239361 Open-Label
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 19 (89.47%)	9 / 9 (100.00%)	6 / 8 (75.00%)
Vascular disorders			
FLUSHING			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
HAEMATOMA			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
PYREXIA			

subjects affected / exposed	5 / 19 (26.32%)	1 / 9 (11.11%)	2 / 8 (25.00%)
occurrences (all)	6	1	2
INJECTION SITE BRUISING			
subjects affected / exposed	3 / 19 (15.79%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	3	2	0
INJECTION SITE RASH			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	3
CHILLS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE HAEMORRHAGE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE IRRITATION			
subjects affected / exposed	0 / 19 (0.00%)	5 / 9 (55.56%)	0 / 8 (0.00%)
occurrences (all)	0	23	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE PAIN			
subjects affected / exposed	2 / 19 (10.53%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	5	0	1
FATIGUE			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE DISCOMFORT			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE ERYTHEMA			
subjects affected / exposed	1 / 19 (5.26%)	4 / 9 (44.44%)	0 / 8 (0.00%)
occurrences (all)	2	6	0
INJECTION SITE SWELLING			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE REACTION			

subjects affected / exposed	0 / 19 (0.00%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE OEDEMA			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
INJECTION SITE PRURITUS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
SEASONAL ALLERGY			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
TESTICULAR TORSION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	2 / 19 (10.53%)	1 / 9 (11.11%)	4 / 8 (50.00%)
occurrences (all)	2	1	5
EPISTAXIS			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
NASAL CONGESTION			
subjects affected / exposed	1 / 19 (5.26%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	1	3	0
PRODUCTIVE COUGH			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
ASTHMA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
HICCUPS			

subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
NASAL DISCHARGE DISCOLOURATION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
PARANASAL SINUS HYPERSECRETION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	2 / 19 (10.53%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	4	0	0
RHINORRHOEA			
subjects affected / exposed	2 / 19 (10.53%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
BRONCHOSPASM			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
LOWER RESPIRATORY TRACT CONGESTION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
PLEURAL EFFUSION			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
RHINITIS ALLERGIC			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SLEEP APNOEA SYNDROME			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
BRUXISM			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
ANGER			

subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
ENURESIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Investigations			
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
LYMPH NODE PALPABLE			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
ARTHROPOD BITE			
subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
CONTUSION			
subjects affected / exposed	0 / 19 (0.00%)	4 / 9 (44.44%)	0 / 8 (0.00%)
occurrences (all)	0	5	0
FALL			
subjects affected / exposed	1 / 19 (5.26%)	7 / 9 (77.78%)	0 / 8 (0.00%)
occurrences (all)	1	20	0
LIGAMENT SPRAIN			
subjects affected / exposed	1 / 19 (5.26%)	2 / 9 (22.22%)	1 / 8 (12.50%)
occurrences (all)	1	2	1
SKIN ABRASION			
subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
EYELID CONTUSION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
FOOT FRACTURE			
subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
POST-TRAUMATIC PAIN			

subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
THERMAL BURN			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
EYE CONTUSION			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
HEAD INJURY			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
UPPER LIMB FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
CORNEAL ABRASION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
FIBULA FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
JOINT INJURY			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
LIMB INJURY			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
PROCEDURAL PAIN			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SKIN LACERATION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SOFT TISSUE INJURY			

subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
SUNBURN			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
TIBIA FRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Congenital, familial and genetic disorders			
DERMOID CYST			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
SINUS TACHYCARDIA			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
CARDIOMYOPATHY			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
LEFT VENTRICULAR DYSFUNCTION			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
MYOCARDIAL FIBROSIS			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
HEADACHE			
subjects affected / exposed	7 / 19 (36.84%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	19	3	0
DIZZINESS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
MOTOR DYSFUNCTION			

subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
SINUS HEADACHE			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
EAR PAIN			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
TYMPANIC MEMBRANE PERFORATION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
TYMPANIC MEMBRANE HYPERAEMIA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
CATARACT			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
DIARRHOEA			
subjects affected / exposed	2 / 19 (10.53%)	1 / 9 (11.11%)	1 / 8 (12.50%)
occurrences (all)	2	1	3
VOMITING			
subjects affected / exposed	4 / 19 (21.05%)	4 / 9 (44.44%)	1 / 8 (12.50%)
occurrences (all)	4	11	1
ABDOMINAL PAIN UPPER			
subjects affected / exposed	2 / 19 (10.53%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	2	1	0
ABDOMINAL PAIN			

subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
BREATH ODOUR			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
CONSTIPATION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
DYSPEPSIA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
LIP SWELLING			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
MOUTH ULCERATION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
GASTRIC ULCER			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
HAEMATOCHEZIA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
MALPOSITIONED TEETH			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
MUCOUS STOOLS			

subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
RASH			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
DERMATITIS CONTACT			
subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
SKIN ULCER			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
DRY SKIN			
subjects affected / exposed	2 / 19 (10.53%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
ERYTHEMA			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
INGROWING NAIL			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
ACNE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
COLD SWEAT			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
EPHELIDES			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
LIVEDO RETICULARIS			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0

PRURITUS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
POLYURIA			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
NEPHROLITHIASIS			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			
ADRENAL INSUFFICIENCY			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
CUSHINGOID			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
DELAYED PUBERTY			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 19 (0.00%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
BACK PAIN			
subjects affected / exposed	1 / 19 (5.26%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	1	2	0
JOINT SWELLING			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

ARTHRALGIA			
subjects affected / exposed	1 / 19 (5.26%)	3 / 9 (33.33%)	0 / 8 (0.00%)
occurrences (all)	1	3	0
MYALGIA			
subjects affected / exposed	1 / 19 (5.26%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
JOINT CONTRACTURE			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
OSTEOPOROSIS			
subjects affected / exposed	0 / 19 (0.00%)	2 / 9 (22.22%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
COCCYDYNIA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
COSTOCHONDRITIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
INTERVERTEBRAL DISC COMPRESSION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
MUSCLE TIGHTNESS			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
PAIN IN JAW			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SYNOVIAL CYST			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			

UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	4 / 19 (21.05%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	5	0	1
NASOPHARYNGITIS			
subjects affected / exposed	4 / 19 (21.05%)	4 / 9 (44.44%)	1 / 8 (12.50%)
occurrences (all)	4	7	2
EAR INFECTION			
subjects affected / exposed	0 / 19 (0.00%)	2 / 9 (22.22%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
PHARYNGITIS STREPTOCOCCAL			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
SINUSITIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
NAIL INFECTION			
subjects affected / exposed	1 / 19 (5.26%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
INFLUENZA			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
PHARYNGITIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
ABSCESS ORAL			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
BODY TINEA			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
CONJUNCTIVITIS			

subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
FUNGAL SKIN INFECTION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
LABYRINTHITIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
ONYCHOMYCOSIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
PNEUMONIA MYCOPLASMAL			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SCARLET FEVER			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SKIN CANDIDA			
subjects affected / exposed	0 / 19 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
STAPHYLOCOCCAL SKIN INFECTION			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
TOOTH ABSCESS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
VIRAL RHINITIS			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	0 / 19 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Panel 3 and Expansion Panel RO7239361 Open-Label		

Total subjects affected by non-serious adverse events subjects affected / exposed	24 / 26 (92.31%)		
Vascular disorders			
FLUSHING			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
HAEMATOMA			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	4 / 26 (15.38%)		
occurrences (all)	8		
INJECTION SITE BRUISING			
subjects affected / exposed	6 / 26 (23.08%)		
occurrences (all)	13		
INJECTION SITE RASH			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
CHILLS			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
INJECTION SITE HAEMORRHAGE			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	2		
INJECTION SITE IRRITATION			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
PERIPHERAL SWELLING			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
INJECTION SITE PAIN			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	3		
FATIGUE			

subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
INJECTION SITE DISCOMFORT			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
INJECTION SITE ERYTHEMA			
subjects affected / exposed	8 / 26 (30.77%)		
occurrences (all)	13		
INJECTION SITE SWELLING			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
INJECTION SITE REACTION			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
INJECTION SITE OEDEMA			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
INJECTION SITE PRURITUS			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Immune system disorders			
SEASONAL ALLERGY			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	4		
Reproductive system and breast disorders			
TESTICULAR TORSION			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	7 / 26 (26.92%)		
occurrences (all)	11		
EPISTAXIS			

subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	13			
NASAL CONGESTION				
subjects affected / exposed	5 / 26 (19.23%)			
occurrences (all)	5			
PRODUCTIVE COUGH				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
ASTHMA				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
HICCUPS				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
NASAL DISCHARGE DISCOLOURATION				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
PARANASAL SINUS HYPERSECRETION				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
OROPHARYNGEAL PAIN				
subjects affected / exposed	4 / 26 (15.38%)			
occurrences (all)	6			
RHINORRHOEA				
subjects affected / exposed	3 / 26 (11.54%)			
occurrences (all)	5			
BRONCHOSPASM				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
LOWER RESPIRATORY TRACT CONGESTION				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
PLEURAL EFFUSION				

subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
RHINITIS ALLERGIC			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
SLEEP APNOEA SYNDROME			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Psychiatric disorders			
BRUXISM			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
ANGER			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
ENURESIS			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
Investigations			
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
LYMPH NODE PALPABLE			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
ARTHROPOD BITE			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
CONTUSION			
subjects affected / exposed	4 / 26 (15.38%)		
occurrences (all)	4		
FALL			
subjects affected / exposed	6 / 26 (23.08%)		
occurrences (all)	8		
LIGAMENT SPRAIN			

subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	2			
SKIN ABRASION				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
EYELID CONTUSION				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
FOOT FRACTURE				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
POST-TRAUMATIC PAIN				
subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	2			
THERMAL BURN				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
EYE CONTUSION				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
HEAD INJURY				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
UPPER LIMB FRACTURE				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
CORNEAL ABRASION				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
FIBULA FRACTURE				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
HUMERUS FRACTURE				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
JOINT INJURY				

subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
LIMB INJURY			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	2		
PROCEDURAL PAIN			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
SKIN LACERATION			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
SOFT TISSUE INJURY			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
SUNBURN			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
TIBIA FRACTURE			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Congenital, familial and genetic disorders			
DERMOID CYST			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
SINUS TACHYCARDIA			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
CARDIOMYOPATHY			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
LEFT VENTRICULAR DYSFUNCTION			

subjects affected / exposed occurrences (all) MYOCARDIAL FIBROSIS subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0 0 / 26 (0.00%) 0		
Nervous system disorders HEADACHE subjects affected / exposed occurrences (all) DIZZINESS subjects affected / exposed occurrences (all) MOTOR DYSFUNCTION subjects affected / exposed occurrences (all) SINUS HEADACHE subjects affected / exposed occurrences (all)	 9 / 26 (34.62%) 27 1 / 26 (3.85%) 1 0 / 26 (0.00%) 0 0 / 26 (0.00%) 0		
Ear and labyrinth disorders EAR PAIN subjects affected / exposed occurrences (all) TYMPANIC MEMBRANE PERFORATION subjects affected / exposed occurrences (all) TYMPANIC MEMBRANE HYPERAEMIA subjects affected / exposed occurrences (all)	 1 / 26 (3.85%) 1 0 / 26 (0.00%) 0 1 / 26 (3.85%) 1		
Eye disorders CATARACT subjects affected / exposed occurrences (all) DRY EYE subjects affected / exposed occurrences (all) VISION BLURRED	 1 / 26 (3.85%) 1 1 / 26 (3.85%) 1		

subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
DIARRHOEA			
subjects affected / exposed	9 / 26 (34.62%)		
occurrences (all)	14		
VOMITING			
subjects affected / exposed	8 / 26 (30.77%)		
occurrences (all)	9		
ABDOMINAL PAIN UPPER			
subjects affected / exposed	3 / 26 (11.54%)		
occurrences (all)	11		
ABDOMINAL PAIN			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
BREATH ODOUR			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
CONSTIPATION			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
DYSPEPSIA			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
LIP SWELLING			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
MOUTH ULCERATION			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
NAUSEA			
subjects affected / exposed	3 / 26 (11.54%)		
occurrences (all)	3		

GASTRIC ULCER subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0			
ABDOMINAL PAIN LOWER subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1			
HAEMATOCHEZIA subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 3			
MALPOSITIONED TEETH subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1			
MUCOUS STOOLS subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1			
RECTAL HAEMORRHAGE subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1			
Skin and subcutaneous tissue disorders RASH subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 3			
DERMATITIS CONTACT subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0			
SKIN ULCER subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0			
DRY SKIN subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0			
ERYTHEMA subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0			
INGROWING NAIL				

subjects affected / exposed occurrences (all) ACNE subjects affected / exposed occurrences (all) COLD SWEAT subjects affected / exposed occurrences (all) EPHELIDES subjects affected / exposed occurrences (all) LIVEDO RETICULARIS subjects affected / exposed occurrences (all) PRURITUS subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0 1 / 26 (3.85%) 1 1 / 26 (3.85%) 1 1 / 26 (3.85%) 1 0 / 26 (0.00%) 0 1 / 26 (3.85%) 1		
Renal and urinary disorders POLYURIA subjects affected / exposed occurrences (all) NEPHROLITHIASIS subjects affected / exposed occurrences (all)	 0 / 26 (0.00%) 0 0 / 26 (0.00%) 0		
Endocrine disorders ADRENAL INSUFFICIENCY subjects affected / exposed occurrences (all) CUSHINGOID subjects affected / exposed occurrences (all) DELAYED PUBERTY subjects affected / exposed occurrences (all)	 1 / 26 (3.85%) 1 2 / 26 (7.69%) 2 0 / 26 (0.00%) 0		
Musculoskeletal and connective tissue disorders			

PAIN IN EXTREMITY				
subjects affected / exposed	4 / 26 (15.38%)			
occurrences (all)	4			
BACK PAIN				
subjects affected / exposed	5 / 26 (19.23%)			
occurrences (all)	5			
JOINT SWELLING				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
MUSCLE SPASMS				
subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	2			
NECK PAIN				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
ARTHRALGIA				
subjects affected / exposed	3 / 26 (11.54%)			
occurrences (all)	4			
MYALGIA				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
JOINT CONTRACTURE				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
OSTEOPOROSIS				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
MUSCULAR WEAKNESS				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
COCCYDYNIA				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
COSTOCHONDRITIS				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			

INTERVERTEBRAL DISC COMPRESSION			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	2		
MUSCLE TIGHTNESS			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
PAIN IN JAW			
subjects affected / exposed	1 / 26 (3.85%)		
occurrences (all)	1		
SYNOVIAL CYST			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
Infections and infestations			
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	11 / 26 (42.31%)		
occurrences (all)	25		
NASOPHARYNGITIS			
subjects affected / exposed	7 / 26 (26.92%)		
occurrences (all)	12		
EAR INFECTION			
subjects affected / exposed	4 / 26 (15.38%)		
occurrences (all)	5		
PHARYNGITIS STREPTOCOCCAL			
subjects affected / exposed	3 / 26 (11.54%)		
occurrences (all)	4		
SINUSITIS			
subjects affected / exposed	2 / 26 (7.69%)		
occurrences (all)	3		
NAIL INFECTION			
subjects affected / exposed	0 / 26 (0.00%)		
occurrences (all)	0		
INFLUENZA			
subjects affected / exposed	3 / 26 (11.54%)		
occurrences (all)	5		
PHARYNGITIS			

subjects affected / exposed	2 / 26 (7.69%)			
occurrences (all)	3			
GASTROENTERITIS VIRAL				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
ABSCESS ORAL				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
BODY TINEA				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
CONJUNCTIVITIS				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
FUNGAL SKIN INFECTION				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
LABYRINTHITIS				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
ONYCHOMYCOSIS				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
PNEUMONIA MYCOPLASMAL				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
SCARLET FEVER				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
SKIN CANDIDA				
subjects affected / exposed	0 / 26 (0.00%)			
occurrences (all)	0			
STAPHYLOCOCCAL SKIN INFECTION				
subjects affected / exposed	1 / 26 (3.85%)			
occurrences (all)	1			
TOOTH ABSCESS				

subjects affected / exposed occurrences (all) VIRAL RHINITIS subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1 1 / 26 (3.85%) 1		
Metabolism and nutrition disorders DECREASED APPETITE subjects affected / exposed occurrences (all)	 0 / 26 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 September 2015	Updated schedule and clarified data to be included in the interim analyses. Added additional laboratory assessments for additional safety monitoring and added storage of residual plasma sample remaining after glutamate dehydrogenase (GLDH) analysis for up to five years after the last subject's last study visit. Clarified the secondary and exploratory endpoints associated with magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) procedures and clarified that MRS will be conducted at selected sites as training is completed.
09 December 2015	Removed ACTIVE assessment from study procedures. Clarified inclusion/exclusion criteria. Updated number of planned interim analyses.
21 April 2016	Clarification added after the withdrawal of study drug into an appropriate-sized syringe, the product should be administered SC within 4 hours to align with our current investigational brochure. Updated safety information. Removed the exclusion criteria: baseline 4SC 9 Day -1) more than a 20% or 0.5 second reduction, whichever is greater, from the valid screening 4SC 9 Day -45 to Day -7) used to determine eligibility.
21 February 2017	Added open-label extension (OLE) phase to the study. Updated plan for clinical study reports.
21 August 2017	Changed Sponsor from Bristol-Myers Squibb to F. Hoffmann-La Roche Ltd. Changed study drug name from BMS-986089 to RO7239361.
14 October 2018	Changed investigational medicinal product (IMP) dose in the open-label extension (OLE) phase date stamp. Changed IMP from vial to prefilled syringes (PFS) in the OLE. Changed the study assessments and procedures to add a new clinic visits, pharmacokinetic/pharmacodynamic (PK/PD) and safety assessments after the switch to PFS. Product Development Background and Overall Risk/Benefit sections were updated. Updated monitoring of anti-drug antibodies (ADAs) during 24-week follow-up period Deleted references to BMS study and drug number.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
15 April 2020	A pre-planned futility analysis indicated lack of efficacy in study WN40227/2016-001654-18 and led to discontinuation of both ongoing studies in DMD (WN40226/2015-005455 and WN40227/2016-001654-18).	-

Notes:

Limitations and caveats

None reported